International Assets Investment Management LLC Invests $29,000 in MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA)

International Assets Investment Management LLC purchased a new stake in MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 25,000 shares of the company’s stock, valued at approximately $29,000. International Assets Investment Management LLC owned approximately 0.15% of MIRA Pharmaceuticals at the end of the most recent reporting period.

Separately, Suncoast Equity Management increased its position in shares of MIRA Pharmaceuticals by 125.0% in the 3rd quarter. Suncoast Equity Management now owns 90,000 shares of the company’s stock worth $117,000 after purchasing an additional 50,000 shares during the last quarter. 35.16% of the stock is owned by institutional investors.

MIRA Pharmaceuticals Price Performance

MIRA stock opened at $1.17 on Wednesday. The firm has a market cap of $19.38 million, a price-to-earnings ratio of -2.09 and a beta of 2.12. MIRA Pharmaceuticals, Inc. has a 1-year low of $0.51 and a 1-year high of $5.01. The firm has a fifty day moving average price of $1.28 and a two-hundred day moving average price of $1.43.

MIRA Pharmaceuticals (NASDAQ:MIRA) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.14) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.04. As a group, analysts expect that MIRA Pharmaceuticals, Inc. will post -0.6 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on MIRA shares. Rodman & Renshaw initiated coverage on shares of MIRA Pharmaceuticals in a research report on Monday, September 30th. They set a “buy” rating and a $17.00 price target on the stock. RODMAN&RENSHAW raised MIRA Pharmaceuticals to a “strong-buy” rating in a report on Monday, September 30th.

Insider Activity

In related news, CEO Erez Aminov sold 55,410 shares of the stock in a transaction dated Tuesday, November 19th. The shares were sold at an average price of $1.39, for a total value of $77,019.90. Following the sale, the chief executive officer now owns 1,105,790 shares of the company’s stock, valued at $1,537,048.10. This trade represents a 4.77 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 6.65% of the company’s stock.

About MIRA Pharmaceuticals

MIRA Pharmaceuticals, Inc operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder.